Talk:Kanna: Difference between revisions
>Planlos69 No edit summary |
>Brack →Pharmacology: correction of mechanism of action misinformation |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 45: | Line 45: | ||
==Pharmacology== | ==Pharmacology== | ||
{{pharmacology}} | {{pharmacology}} | ||
The main psychoactive effects of kanna are a result of its action as a potent serotonin reuptake inhibitor ([[SRI]]), a [https://en.wikipedia.org/wiki/Phosphodiesterase-4_inhibitor PDE4 inhibitor], and | The main psychoactive effects of kanna are a result of its action as a potent serotonin reuptake inhibitor ([[SRI]]), a [https://en.wikipedia.org/wiki/Phosphodiesterase-4_inhibitor PDE4 inhibitor], and a monoamine releasing agent. <ref>https://www.sciencedirect.com/science/article/pii/S0378874115302348?via%3Dihub</ref>. | ||
The VMAT2 upregulation produced by kanna is a compensatory response produced by stimulants such as cocaine and methylphenidate <ref>https://pubmed.ncbi.nlm.nih.gov/16897597/</ref>. However, some online users have misinterpreted the findings of VMAT2 upregulation from kanna as evidence of being a different type of stimulant. This is false, and monoamine releasing agents upregulate VMAT2 as a compensatory mechanism, involved in tolerance. VMAT2 upregulation is evidence that a compound acts similar to monoamine releasers like cocaine and methylphenidate <ref>https://pmc.ncbi.nlm.nih.gov/articles/PMC6757793/</ref> | |||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- |